| 4.4 0.04 (0.92%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.46 | 1-year : | 5.87 |
| Resists | First : | 4.67 | Second : | 5.03 |
| Pivot price | 4.32  |
|||
| Supports | First : | 4.09 | Second : | 3.41 |
| MAs | MA(5) : | 4.36 |
MA(20) : | 4.42 |
| MA(100) : | 5.75 |
MA(250) : | 6.93 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 31.8 |
D(3) : | 32.5 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 12.8 | Low : | 4.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BHST ] has closed below upper band by 39.0%. Bollinger Bands are 63.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.62 - 4.63 | 4.63 - 4.65 |
| Low: | 4.35 - 4.37 | 4.37 - 4.39 |
| Close: | 4.37 - 4.4 | 4.4 - 4.43 |
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.
Wed, 03 Dec 2025
BioHarvest (NASDAQ: BHST) debuts VINIA Blood Flow Hydration online in US market - Stock Titan
Wed, 10 Sep 2025
BioHarvest Sciences: Growth Story Meets Valuation Reality - Seeking Alpha
Sat, 18 Jan 2025
Should I buy BioHarvest Sciences Inc. (BHST) - Zacks Investment Research
Fri, 06 Dec 2024
BioHarvest Sciences (BHST) Stock Price, News & Analysis - MarketBeat
Sun, 17 Nov 2024
BioHarvest Sciences Inc. Common Stock (BHST) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Basic Materials
|
|
|
Industry:
Agricultural Inputs
|
|
| Shares Out | 23 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 22.2 (%) |
| Held by Institutions | 8.1 (%) |
| Shares Short | 63 (K) |
| Shares Short P.Month | 61 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.38 |
| Profit Margin | -36.4 % |
| Operating Margin | -10.2 % |
| Return on Assets (ttm) | -12.6 % |
| Return on Equity (ttm) | -200.3 % |
| Qtrly Rev. Growth | 38.7 % |
| Gross Profit (p.s.) | 0.85 |
| Sales Per Share | 1.44 |
| EBITDA (p.s.) | -0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -6.48 |
| PEG Ratio | 0 |
| Price to Book value | 11.28 |
| Price to Sales | 3.04 |
| Price to Cash Flow | -13.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|